Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12620000349943
Ethics application status
Approved
Date submitted
6/03/2020
Date registered
12/03/2020
Date last updated
3/04/2024
Date data sharing statement initially provided
12/03/2020
Type of registration
Prospectively registered

Titles & IDs
Public title
Instylla Hydrogel Embolic System Pilot Study For Patients Requiring Transcatheter Embolization of Vascular Bleeds
Scientific title
A Prospective, Non-Randomized Single-Arm Pilot Study to Assess the Safety and Effectiveness of Instylla Hydrogel Embolic System (HES) For Transcatheter Embolization of Vascular Bleeds
Secondary ID [1] 300733 0
INY-P-20-002
Universal Trial Number (UTN)
U1111-1249-3159
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Patients Requiring Transcatheter Embolization of Vascular Bleeds 316556 0
Condition category
Condition code
Emergency medicine 314794 314794 0 0
Other emergency care

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Instylla Hydrogel Embolic System (HES) including Instylla Delivery Kit and Instylla Microcatheter.
This involvement for the patient is the same procedures, activities and processes used for standard vascular embolization procedures.
Subjects will be treated within this protocol by an interventionalist with substantial prior experience with vascular embolization procedure.
The mode of delivery will be performed face to face and the location will be at the hospital.
The number of interventions that will be delivered will be one time and possible more over the 30 day follow-up period. The procedure will take about the same time as a standard embolic procedure (about 30 minutes to an hour).
The interventionalist will decide if more procedures are administered.
Intervention code [1] 317056 0
Treatment: Devices
Comparator / control treatment
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 323158 0
Incidence of serious device and serious procedure-related adverse events and non target embolization. Events will be reviewed by an Independent Medical Monitor. (composite endpoint) There are no known unique risks associated with the Instylla HES. Throughout the duration of the study, subjects will be clinically evaluated (imaging and blood lab tests) and assessed for adverse events using the grading of the NCI Common Terminology Criteria for Adverse Events (CTCAE Version 5.0). Severity of complications will be further classified in accordance with Society of Interventional Radiology (SIR) guidelines.
Timepoint [1] 323158 0
30 days post-embolization
Secondary outcome [1] 380972 0
Technical success of achieving embolization demonstrated by post procedure angiography.
Timepoint [1] 380972 0
Immediately after embolisation procedure

Eligibility
Key inclusion criteria
1. Male or female patients age greater than or equal to 18 years old
2. Transcatheter vascular embolization of vascular bleeds is clinically indicated
3. Positive angiographic findings of bleeding
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Ongoing adverse effect that may confound the evaluation of the Instylla HES
2. Pregnant females
3. The patient has other concurrent conditions or known history that in the opinion of the Investigator would be unlikely to receive clinical benefit from the study procedure or participation in the study may compromise patient safety or study objectives (including but not limited to ongoing infection, morbid obesity).

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Data analysis is complete
Reason for early stopping/withdrawal
Other reasons/comments
Other reasons
The study was prematurely terminated because of the situation that arose after the COVID-19 pandemic hit. Site locations were closed, and clinical studies put on hold worldwide. Once sites were opened and studies allowed, Instylla Inc. decided to investigate Instylla HES in a large-scale clinical investigation in other geographical locations.
Date of first participant enrolment
Anticipated
15/02/2021
Actual
4/06/2021
Date of last participant enrolment
Anticipated
Actual
8/11/2021
Date of last data collection
Anticipated
Actual
8/12/2021
Sample size
Target
15
Accrual to date
Final
2
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 305184 0
Commercial sector/Industry
Name [1] 305184 0
Instylla Inc
Country [1] 305184 0
United States of America
Primary sponsor type
Commercial sector/Industry
Name
Instylla Inc
Address
201 Burlington Road Bedford, MA 01730
Country
United States of America
Secondary sponsor category [1] 305539 0
Commercial sector/Industry
Name [1] 305539 0
Avania Pty Ltd
Address [1] 305539 0
13/76 Reserve Road, Artarmon NSW 2064
Country [1] 305539 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 305540 0
Alfred Hospital Ethics Committee https://www.alfredhealth.org.au/research/ethics-research-governance
Ethics committee address [1] 305540 0
Ethics committee country [1] 305540 0
Australia
Date submitted for ethics approval [1] 305540 0
23/03/2020
Approval date [1] 305540 0
11/06/2020
Ethics approval number [1] 305540 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 100722 0
Dr Gerard Goh
Address 100722 0
Radiology Dept. The Alfred 55 Commercial Road, Melbourne Vic. 3004
Country 100722 0
Australia
Phone 100722 0
+61 3 9076 3630
Fax 100722 0
Email 100722 0
g.goh@alfred.org.au
Contact person for public queries
Name 100723 0
Nicole Rissman
Address 100723 0
201 Burlington Road Bedford, MA 01730
Country 100723 0
United States of America
Phone 100723 0
+1 781 790 4860
Fax 100723 0
Email 100723 0
nicoler@instylla.com
Contact person for scientific queries
Name 100724 0
Nicole Rissman
Address 100724 0
201 Burlington Road Bedford, MA 01730
Country 100724 0
United States of America
Phone 100724 0
+1 781 790 4860
Fax 100724 0
Email 100724 0
nicoler@instylla.com

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.